FDA declines to define ‘natural’
In a much anticipated letter response, the Food and Drug Administration (FDA) has officially declined the opportunity to administratively determine whether foods containing bio-engineered ingredients may be labelled as ‘natural’, ‘all natural’ or ‘100 per cent natural’ and, more generally, declined the opportunity to define ‘natural’ in the context of food labelling.
The issue stems from an influx of litigation involving the alleged false advertising of food products making a variety of ‘natural’ claims, where no official federal law, rule or regulation defines the term ‘natural’. Three separate US.S District Court cases — Cox v Gruma Corp (ND Cal), Barnes v Campbell Soup Co (ND Cal) and In re General Mills Inc Kix Cereal Litigation (DNJ) — referred the issue to the FDA on primary jurisdiction grounds for the FDA’s determination as to whether food products containing corn from genetically modified seeds could be labelled ‘natural’.
As stated in the FDA’s 6 January letter, despite significant push from industry and consumer groups alike, FDA declined to allocate its resources ‘at this time’ to make a determination regarding whether and under what circumstances food products containing genetically engineered ingredients may be labelled ‘natural’…
If you are registered and logged in to the site, click on the link below to read the rest of the DLA Piper briefing. If not, please register or sign in with your details below.
News from DLA Piper
News from The Lawyer
Briefings from DLA Piper
Global Financial Markets Insight — the case for a better-functioning securitisation market; the cost of holding ABS; and more
DLA Piper has released the latest version (issue 4, Q3 2014) of its Global Financial Markets Insight publication.
Corporate Insurance Trends 2014 is a collection of articles highlighting some trends and key issues for financial lines insurers and their insureds in 2014.
Analysis from The Lawyer
Shearman & Sterling is making its presence felt in the City, squaring up to magic circle firms and looking to muscle in on key relationships. Private equity house Bridgepoint is one outfit that has had its head turned by the US firm.
A new breed of lawyer is smoothing the path for companies entering emerging or unstable jurisdictions